Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Inflammopharmacology
Published in: Inflammopharmacology 5/2022

21-08-2022 | Atorvastatin | Review

The effect of statin therapy in combination with ezetimibe on circulating C-reactive protein levels: a systematic review and meta-analysis of randomized controlled trials

Authors: Seyyed Mostafa Arabi, Mahla Chambari, Mahsa Malek-Ahmadi, Leila Sadat Bahrami, Vahid Hadi, Manfredi Rizzo, Amirhossein Sahebkar

Published in: Inflammopharmacology | Issue 5/2022

Login to get access

Abstract

Background

Previous studies have reported that statin or ezetimibe therapy has an anti-inflammatory effect. However, the results of individual studies on the effect of statin therapy in combination with ezetimibe on C-reactive protein (CRP) and high-sensitivity CRP (hs-CRP) levels have not been clear. Therefore, the present systematic review and meta-analysis were conducted on randomized clinical trials (RCTs) to evaluate the effect of statin therapy in combination with ezetimibe on CRP and hs-CRP levels.

Methods

A literature search was carried out on the MEDLINE, SciVerse Scopus, and Clarivate Analytics Web of Science databases up to February 2022 to find eligible studies. The pooled effect sizes were considered for weighted mean difference (WMD) and 95% confidence intervals (CI) for CRP and hs-CRP, and it was also determined as standardized weighted mean difference (SMD) for overall CRP. For all variables, a random-effects model was used.

Results

Of the 57 studies included in the systematic review, 53 were used for meta-analysis. Statin therapy in combination with ezetimibe significantly reduced the serum levels of hs-CRP (WMD − 0.2 mg/l; 95% CI − 0.4, − 0.1, P ˂ 0.001) and overall CRP (SMD − 0.16 mg/l; 95% CI − 0.2, − 0.07, P ˂ 0.001). Nevertheless, CRP levels were not significantly changed by combination therapy. A significant association was observed between the serum low-density lipoprotein cholesterol (LDL-C) changes and hs-CRP levels, which can justify the source of heterogeneity.

Conclusions

The current study showed that statin therapy in combination with ezetimibe could be effective in reducing the levels of hs-CRP and overall CRP.

Graphical abstract

Appendix
Available only for authorised users
Literature
Almquist T, Jacobson SH, Lins PE, Farndale RW, Hjemdahl P (2012) Effects of lipid-lowering treatment on platelet reactivity and platelet-leukocyte aggregation in diabetic patients without and with chronic kidney disease: a randomized trial. Nephrol Dial Transplant 27:3540–3546PubMedCrossRef
Alvarez-Sala LA, Cachofeiro V, Masana L, Suarez C, Pinilla B, Plana N, Trias F, Moreno MA, Gambus G, Lahera V, Pintó X (2008) Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study. Clin Ther 30:84–97PubMedCrossRef
An J, Shi F, Liu S, Ma J, Ma Q (2017) Preoperative statins as modifiers of cardiac and inflammatory outcomes following coronary artery bypass graft surgery: a meta-analysis. Interact Cardiovasc Thorac Surg 25:958–965PubMedCrossRef
Arabi SM, Bahrami LS, Milkarizi N, Nematy M, Kalmykov V, Sahebkar A (2022a) Impact of walnut consumption on cardio metabolic and anthropometric parameters in metabolic syndrome patients: GRADE-assessed systematic review and dose-response meta-analysis of data from randomized controlled trials. Pharmacol Res 178:106190PubMedCrossRef
Arabi SM, Bahrami LS, Rahnama I, Sahebkar A (2022b) Impact of synbiotic supplementation on cardiometabolic and anthropometric indices in patients with metabolic syndrome: a systematic review and meta-analysis of randomized controlled trials. Pharmacol Res 176:106061PubMedCrossRef
Araujo DB, Bertolami MC, Ferreira WP, Abdalla DS, Faludi AA, Nakamura Y, Bricharello LP (2010) Pleiotropic effects with equivalent low-density lipoprotein cholesterol reduction: comparative study between simvastatin and simvastatin/ezetimibe coadministration. J Cardiovasc Pharmacol 55:1–5PubMedCrossRef
Arévalo-Lorido JC (2016) Clinical relevance for lowering C-reactive protein with statins. Ann Med 48:516–524PubMedCrossRef
Arimura T, Miura S, Ike A, Sugihara M, Iwata A, Nishikawa H, Kawamura A, Saku K (2012) Comparison of the efficacy and safety of statin and statin/ezetimibe therapy after coronary stent implantation in patients with stable angina. J Cardiol 60:111–118PubMedCrossRef
Azar M, Valentin E, Badaoui G, Kassab R, Sarkis A, Azar RR (2011) Comparison of the effects of combination atorvastatin (40 mg) + ezetimibe (10 mg) versus atorvastatin (40 mg) alone on secretory phospholipase A2 activity in patients with stable coronary artery disease or coronary artery disease equivalent. Am J Cardiol 107:1571–1574PubMedCrossRef
Balk EM, Lau J, Goudas LC, Jordan HS, Kupelnick B, Kim LU, Karas RH (2003) Effects of statins on nonlipid serum markers associated with cardiovascular disease: a systematic review. Ann Intern Med 139:670–682PubMedCrossRef
Ballantyne CM, Houri J, Notarbartolo A, Melani L, Lipka LJ, Suresh R, Sun S, Lebeaut AP, Sager PT, Veltri EP (2003) Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 107:2409–2415PubMedCrossRef
Ballantyne CM, Weiss R, Moccetti T, Vogt A, Eber B, Sosef F, Duffield E (2007) Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study). Am J Cardiol 99:673–680PubMedCrossRef
Barbosa SP, Lins LC, Fonseca FA, Matos LN, Aguirre AC, Bianco HT, Amaral JB, França CN, Santana JM, Izar MC (2013) Effects of ezetimibe on markers of synthesis and absorption of cholesterol in high-risk patients with elevated C-reactive protein. Life Sci 92:845–851PubMedCrossRef
Bhagavathula AS, Aldhaleei WA, Al Matrooshi NO, Rahmani J (2020) Efficacy of statin/ezetimibe for secondary prevention of atherosclerotic cardiovascular disease in Asian populations: a systematic review and meta-analysis of randomized controlled trials. Clin Drug Investig 40:809–826PubMedCrossRef
Bland AR, Payne FM, Ashton JC, Jamialahmadi T and Sahebkar A (2022) The cardioprotective actions of statins in targeting mitochondrial dysfunction associated with myocardial ischaemia-reperfusion injury. Pharmacol Res 175
Bohula EA, Giugliano RP, Cannon CP, Zhou J, Murphy SA, White JA, Tershakovec AM, Blazing MA, Braunwald E (2015) Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT. Circulation 132:1224–1233PubMedCrossRef
Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, de Ferrari GM, Ruzyllo W, de Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM, Investigators I-I (2015) Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 372:2387–2397PubMedCrossRef
Catapano AL, Davidson MH, Ballantyne CM, Brady WE, Gazzara RA, Tomassini JE, Tershakovec AM (2006) Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. Curr Med Res Opin 22:2041–2053PubMedCrossRef
Cho YK, Hur SH, Han CD, Park HS, Yoon HJ, Kim H, Nam CW, Kim YN, Kim KB, Park NH, Park HJ (2011) Comparison of ezetimibe/simvastatin 10/20 mg versus atorvastatin 20 mg in achieving a target low density lipoprotein-cholesterol goal for patients with very high risk. Korean Circ J 41:149–153PubMedPubMedCentralCrossRef
Conard SE, Bays HE, Leiter LA, Bird SR, Rubino J, Lowe RS, Tomassini JE, Tershakovec AM (2008) Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease. Am J Cardiol 102:1489–1494PubMedCrossRef
Conard S, Bays H, Leiter LA, Bird S, Lin J, Hanson ME, Shah A, Tershakovec AM (2010) Ezetimibe added to atorvastatin compared with doubling the atorvastatin dose in patients at high risk for coronary heart disease with diabetes mellitus, metabolic syndrome or neither. Diabetes Obes Metab 12:210–218PubMedCrossRef
Dagli N, Yavuzkir M, Karaca I (2007) The effects of high dose pravastatin and low dose pravastatin and ezetimibe combination therapy on lipid, glucose metabolism and inflammation. Inflammation 30:230–235PubMedCrossRef
Davidson MH, Abate N, Ballantyne CM, Catapano AL, Xu X, Lin J, Rosenberg E, Tershakovec AM (2008) Ezetimibe/simvastatin compared with atorvastatin or rosuvastatin in lowering to specified levels both LDL-C and each of five other emerging risk factors for coronary heart disease: non-HDL-cholesterol, TC/HDL-C, apolipoprotein B, apo-B/apo-A-I, or C-reactive protein. J Clin Lipidol 2:436–446PubMedCrossRef
Dehnavi S, Kiani A, Sadeghi M, Biregani AF, Banach M, Atkin SL, Jamialahmadi T, Sahebkar A (2021) Targeting AMPK by statins: a potential therapeutic approach. Drugs 81:923–933PubMedPubMedCentralCrossRef
Devaraj S, Yun JM, Adamson G, Galvez J, Jialal I (2009) C-reactive protein impairs the endothelial glycocalyx resulting in endothelial dysfunction. Cardiovasc Res 84:479–484PubMedPubMedCentralCrossRef
Dong Y, Wang X, Zhang L, Chen Z, Zheng C, Wang J, Kang Y, Shao L, Tian Y, Wang Z (2019) High-sensitivity C reactive protein and risk of cardiovascular disease in China-CVD study. J Epidemiol Community Health 73:188–192PubMedCrossRef
Florentin M, Liberopoulos EN, Moutzouri E, Rizos CV, Tselepis AD, Elisaf MS (2011) The effect of simvastatin alone versus simvastatin plus ezetimibe on the concentration of small dense low-density lipoprotein cholesterol in subjects with primary hypercholesterolemia. Curr Med Res Opin 27:685–692PubMedCrossRef
Garcia MM, Varela CG, Silva PF, Lima PR, Góes PM, Rodrigues MG, Silva Mde L, Ladeia AM, Guimarães AC, Correia LC (2016) Endothelial effect of statin therapy at a high dose versus low dose associated with ezetimibe. Arq Bras Cardiol 106:279–288PubMedPubMedCentral
Goldberg RB, Guyton JR, Mazzone T, Weinstock RS, Polis A, Edwards P, Tomassini JE, Tershakovec AM (2006) Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study. Mayo Clin Proc 81:1579–1588PubMedCrossRef
Gorabi AM, Kiaie N, Bianconi V, Pirro M, Jamialahmadi T, Sahebkar A (2021a) Statins attenuate fibrotic manifestations of cardiac tissue damage. Curr Mol Pharmacol 14:782–797PubMedCrossRef
Gorabi AM, Kiaie N, Pirro M, Bianconi V, Jamialahmadi T, Sahebkar A (2021b) Effects of statins on the biological features of mesenchymal stem cells and therapeutic implications. Heart Fail Rev 26:1259–1272PubMedCrossRef
Hendrani AD, Adesiyun T, Quispe R, Jones SR, Stone NJ, Blumenthal RS, Martin SS (2016) Dyslipidemia management in primary prevention of cardiovascular disease: current guidelines and strategies. World J Cardiol 8:201PubMedPubMedCentralCrossRef
Hibi K, Sonoda S, Kawasaki M, Otsuji Y, Murohara T, Ishii H, Sato K, Koshida R, Ozaki Y, Sata M, Morino Y, Miyamoto T, Amano T, Morita S, Kozuma K, Kimura K, Fujiwara H (2018) Effects of ezetimibe-statin combination therapy on coronary atherosclerosis in acute coronary syndrome. Circ J 82:757–766PubMedCrossRef
Hing Ling PK, Civeira F, Dan AG, Hanson ME, Massaad R, de Tilleghem Cle B, Milardo C, Triscari J (2012) Ezetimibe/simvastatin 10/40 mg versus atorvastatin 40 mg in high cardiovascular risk patients with primary hypercholesterolemia: a randomized, double-blind, active-controlled, multicenter study. Lipids Health Dis 11:18PubMedPubMedCentralCrossRef
Jamialahmadi T, Baratzadeh F, Reiner Ž, Simental-Mendía LE, Xu S, Susekov AV, Santos RD, Sahebkar A (2021) The effects of statin dose, lipophilicity, and combination of statins plus ezetimibe on circulating oxidized low-density lipoprotein levels: a systematic review and meta-analysis of randomized controlled trials. Mediators Inflamm 2021:9661752PubMedPubMedCentralCrossRef
Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA, Hu FB, Hubbard VS, Jakicic JM, Kushner RF, Loria CM, Millen BE, Nonas CA, Pi-Sunyer FX, Stevens J, Stevens VJ, Wadden TA, Wolfe BM, Yanovski SZ, Jordan HS, Kendall KA, Lux LJ, Mentor-Marcel R, Morgan LC, Trisolini MG, Wnek J, Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, Demets D, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK, Smith SC, Tomaselli GF (2014) 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation 129:S102–S138PubMedCrossRef
Jia J, Zhang L, Wang L, Ji C, Xia R, Yang Y (2021) A systematic review and meta-analysis on the efficacy of statins in the treatment of atherosclerosis. Ann Palliat Med 10:6793–6803PubMedCrossRef
Jonathan E, Derrick B, Emma L, Sarah P, John D, Jane A, Rory C (2011) C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20,536 patients in the Heart Protection Study. Lancet 377:469–476CrossRef
Kalogirou M, Tsimihodimos V, Elisaf M (2010) Pleiotropic effects of ezetimibe: do they really exist? Eur J Pharmacol 633:62–70PubMedCrossRef
Kandelouei T, Abbasifard M, Imani D, Aslani S, Razi B, Fasihi M, Shafiekhani S, Mohammadi K, Jamialahmadi T, Reiner Ž (2022) Effect of statins on serum level of hs-CRP and CRP in patients with cardiovascular diseases: a systematic review and meta-analysis of randomized controlled trials. Mediator Inflamm. https://​doi.​org/​10.​1155/​2022/​8732360CrossRef
Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, Visseren FL, Sijbrands EJ, Trip MD, Stein EA, Gaudet D, Duivenvoorden R, Veltri EP, Marais AD, de Groot E (2008) Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 358:1431–1443PubMedCrossRef
Kawagoe Y, Hattori Y, Nakano A, Aoki C, Tanaka S, Ohta S, Iijima T, Tomizawa A, Jojima T, Kase H, Kasai K (2011) Comparative study between high-dose fluvastatin and low-dose fluvastatin and ezetimibe with regard to the effect on endothelial function in diabetic patients. Endocr J 58:171–175PubMedCrossRef
Kim W, Yoon YE, Shin S-H, Bae J-W, Hong B-K, Hong SJ, Sung KC, Han SH, Kim W, Rhee M-Y (2018a) Efficacy and safety of ezetimibe and rosuvastatin combination therapy versus those of rosuvastatin monotherapy in patients with primary hypercholesterolemia. Clin Ther 40:993–1013PubMedCrossRef
Kim W, Yoon YE, Shin SH, Bae JW, Hong BK, Hong SJ, Sung KC, Han SH, Kim W, Rhee MY, Kim SH, Lee SE, Hyon MS, Hwang GS, Son JW, Kim JY, Kim MK, Kim SW, Park JH, Shin JH, Park CG (2018b) Efficacy and safety of ezetimibe and rosuvastatin combination therapy versus those of rosuvastatin monotherapy in patients with primary hypercholesterolemia. Clin Ther 40:993–1013PubMedCrossRef
Koenig W (2013) High-sensitivity C-reactive protein and atherosclerotic disease: from improved risk prediction to risk-guided therapy. Int J Cardiol 168:5126–5134PubMedCrossRef
Kones R (2011) Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey. Drug Des Dev Ther 5:325CrossRef
Krysiak R, Okopien B (2011) The effect of ezetimibe and simvastatin on monocyte cytokine release in patients with isolated hypercholesterolemia. J Cardiovasc Pharmacol 57:505–512PubMedCrossRef
Krysiak R, Zmuda W, Okopien B (2012) The effect of ezetimibe, administered alone or in combination with simvastatin, on lymphocyte cytokine release in patients with elevated cholesterol levels. J Intern Med 271:32–42PubMedCrossRef
Kuhlencordt PJ, Padmapriya P, Rützel S, Schödel J, Hu K, Schäfer A, Huang P, Ertl G, Bauersachs J (2009) Ezetimibe potently reduces vascular inflammation and arteriosclerosis in eNOS-deficient ApoE ko mice. Atherosclerosis 202:48–57PubMedCrossRef
Lambert MNT, Hu LM, Jeppesen PB (2017) A systematic review and meta-analysis of the effects of isoflavone formulations against estrogen-deficient bone resorption in peri- and post-menopausal women. Am J Clin Nutr 106:801–811PubMed
Leiter LA, Bays H, Conard S, Bird S, Rubino J, Hanson ME, Tomassini JE, Tershakovec AM (2008) Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart disease. Am J Cardiol 102:1495–1501PubMedCrossRef
Liao JK (2005) Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol. Am J Cardiol 96:24f–33fPubMedPubMedCentralCrossRef
Libby P, Nahrendorf M, Pittet MJ, Swirski FK (2008) Diversity of denizens of the atherosclerotic plaque: not all monocytes are created equal. Circulation 117:3168–3170PubMedCrossRef
Liu PY, Liu YW, Lin LJ, Chen JH, Liao JK (2009) Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation. Circulation 119:131–138PubMedCrossRef
Liu Z, Hao H, Yin C, Chu Y, Li J, Xu D (2017) Therapeutic effects of atorvastatin and ezetimibe compared with double-dose atorvastatin in very elderly patients with acute coronary syndrome. Oncotarget 8:41582–41589PubMedPubMedCentralCrossRef
Luo P, Li L, Wang LX, Zhu HH, Du S, Wu SL, Han YG, Wang GG (2014) Effects of atorvastatin in combination with ezetimibe on carotid atherosclerosis in elderly patients with hypercholesterolemia. Genet Mol Res 13:2377–2384PubMedCrossRef
Madan M, Vira T, Rampakakis E, Gupta A, Khithani A, Balleza L, Vaillancourt J, Boukas S, Sampalis J, de Carolis E (2012) A randomized trial assessing the effectiveness of ezetimibe in south Asian Canadians with coronary artery disease or diabetes: the INFINITY study. Adv Prev Med 2012:103728PubMedPubMedCentralCrossRef
Masuda J, Tanigawa T, Yamada T, Nishimura Y, Sasou T, Nakata T, Sawai T, Fujimoto N, Dohi K, Miyahara M, Nishikawa M, Nakamura M, Ito M (2015) Effect of combination therapy of ezetimibe and rosuvastatin on regression of coronary atherosclerosis in patients with coronary artery disease. Int Heart J 56:278–285PubMedCrossRef
Mohajeri M, Kovanen PT, Bianconi V, Pirro M, Cicero AFG, Sahebkar A (2019) Mast cell tryptase—marker and maker of cardiovascular diseases. Pharmacol Ther 199:91–110PubMedCrossRef
Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA (2015) Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 4:1–9PubMedPubMedCentralCrossRef
Moutzouri E, Liberopoulos E, Mikhailidis DP, Kostapanos MS, Kei AA, Milionis H, Elisaf M (2011) Comparison of the effects of simvastatin vs. rosuvastatin vs. simvastatin/ezetimibe on parameters of insulin resistance. Int J Clin Pract 65:1141–1148PubMedCrossRef
Oh M, Kim H, Shin EW, Sung C, Kim DH, Moon DH, Lee CW (2019a) Effects of ezetimibe/simvastatin 10/10 mg versus Rosuvastatin 10 mg on carotid atherosclerotic plaque inflammation. BMC Cardiovasc Disord 19:201PubMedPubMedCentralCrossRef
Oh M, Kim H, Shin EW, Sung C, Kim DH, Moon DH, Lee CW (2019b) Effects of ezetimibe/simvastatin 10/10 mg versus Rosuvastatin 10 mg on carotid atherosclerotic plaque inflammation. BMC Cardiovasc Disord 19:201PubMedPubMedCentralCrossRef
Oh M, Kim H, Shin EW, Sung C, Kim DH, Moon DH, Kim N, Eo JS, Kim JW, Lee CW (2020) Comparison of high-dose rosuvastatin versus low-dose rosuvastatin plus ezetimibe on carotid atherosclerotic plaque inflammation in patients with acute coronary syndrome. J Cardiovasc Transl Res 13:900–907PubMedCrossRef
Oh M, Kim H, Shin EW, Sung C, Kim DH, Moon DH, Lee JS, Lee PH, Lee SW, Lee CW (2021) Statin/ezetimibe combination therapy vs statin monotherapy for carotid atherosclerotic plaque inflammation. Medicine (baltimore) 100:e25114CrossRef
Olijhoek JK, Hajer GR, van der Graaf Y, Dallinga-Thie GM, Visseren FL (2008) The effects of low-dose simvastatin and ezetimibe compared to high-dose simvastatin alone on post-fat load endothelial function in patients with metabolic syndrome: a randomized double-blind crossover trial. J Cardiovasc Pharmacol 52:145–150PubMedCrossRef
Ostad MA, Eggeling S, Tschentscher P, Schwedhelm E, Böger R, Wenzel P, Meinertz T, Munzel T, Warnholtz A (2009) Flow-mediated dilation in patients with coronary artery disease is enhanced by high dose atorvastatin compared to combined low dose atorvastatin and ezetimibe: results of the CEZAR study. Atherosclerosis 205:227–232PubMedCrossRef
Panichi V, Manca-Rizza G, Paoletti S, Taccola D, Consani C, Sbragia G, Mantuano E, Marchetti V, Carpi A, Barsotti G (2006) Safety and effects on the lipid and C-reactive protein plasma concentration of the association of ezetimibe plus atorvastatin in renal transplant patients treated by cyclosporine-A: a pilot study. Biomed Pharmacother 60:249–252PubMedCrossRef
Parrinello CM, Lutsey PL, Ballantyne CM, Folsom AR, Pankow JS, Selvin E (2015) Six-year change in high-sensitivity C-reactive protein and risk of diabetes, cardiovascular disease, and mortality. Am Heart J 170:380–389PubMedPubMedCentralCrossRef
Pearson TA, Denke MA, McBride PE, Battisti WP, Gazzara RA, Brady WE, Palmisano J (2006) Effectiveness of ezetimibe added to ongoing statin therapy in modifying lipid profiles and low-density lipoprotein cholesterol goal attainment in patients of different races and ethnicities: a substudy of the Ezetimibe add-on to statin for effectiveness trial. Mayo Clin Proc 81:1177–1185PubMedCrossRef
Pesaro AE, Serrano CV Jr, Fernandes JL, Cavalcanti AB, Campos AH, Martins HS, Maranhão RC, de Lemos JA, Souza HP, Nicolau JC (2012) Pleiotropic effects of ezetimibe/simvastatin vs. high dose simvastatin. Int J Cardiol 158:400–404PubMedCrossRef
Ramkumar S, Raghunath A, Raghunath S (2016) Statin therapy: review of safety and potential side effects. Acta Cardiologica Sinica 32:631PubMedPubMedCentral
Ran D, Nie HJ, Gao YL, Deng SB, Du JL, Liu YJ, Jing XD, She Q (2017) A randomized, controlled comparison of different intensive lipid-lowering therapies in Chinese patients with non-ST-elevation acute coronary syndrome (NSTE-ACS): ezetimibe and rosuvastatin versus high-dose rosuvastatin. Int J Cardiol 235:49–55PubMedCrossRef
Rauch U, Osende JI, Chesebro JH, Fuster V, Vorchheimer DA, Harris K, Harris P, Sandler DA, Fallon JT, Jayaraman S, Badimon JJ (2000) Statins and cardiovascular diseases: the multiple effects of lipid-lowering therapy by statins. Atherosclerosis 153:181–189PubMedCrossRef
Reckless JP, Henry P, Pomykaj T, Lim ST, Massaad R, Vandormael K, Johnson-Levonas AO, Lis K, Brudi P, Allen C (2008) Lipid-altering efficacy of ezetimibe/simvastatin 10/40 mg compared with doubling the statin dose in patients admitted to the hospital for a recent coronary event: the INFORCE study. Int J Clin Pract 62:539–554PubMedCrossRef
Reiner Ž, Hatamipour M, Banach M, Pirro M, Al-Rasadi K, Jamialahmadi T, Radenkovic D, Montecucco F, Sahebkar A (2020) Statins and the Covid-19 main protease: in silico evidence on direct interaction. Arch Med Sci 16:490–496PubMedPubMedCentralCrossRef
Ren Y, Zhu H, Fan Z, Gao Y, Tian N (2017) Comparison of the effect of rosuvastatin versus rosuvastatin/ezetimibe on markers of inflammation in patients with acute myocardial infarction. Exp Ther Med 14:4942–4950PubMedPubMedCentral
Ridker PM, Buring JE, Rifai N, Cook NR (2007) Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA 297:611–619PubMedCrossRef
Robinson JG, Ballantyne CM, Grundy SM, Hsueh WA, Parving HH, Rosen JB, Adewale AJ, Polis AB, Tomassini JE, Tershakovec AM (2009) Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study). Am J Cardiol 103:1694–1702PubMedCrossRef
Robinson JG, Ballantyne CM, Hsueh W, Rosen J, Lin J, Shah A, Lowe RS, Hanson ME, Tershakovec AM (2011) Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study). J Clin Lipidol 5:474–482PubMedCrossRef
Rosen JB, Jimenez JG, Pirags V, Vides H, Hanson ME, Massaad R, McPeters G, Brudi P, Triscari J (2013) A comparison of efficacy and safety of an ezetimibe/simvastatin combination compared with other intensified lipid-lowering treatment strategies in diabetic patients with symptomatic cardiovascular disease. Diab Vasc Dis Res 10:277–286PubMedCrossRef
Rudofsky G, Reismann P, Groener JB, Djuric Z, Fleming T, Metzner C, Grafe IA, Bierhaus A, Nawroth PP (2012) Identical LDL-cholesterol lowering but non-identical effects on NF-κB activity: High dose simvastatin vs combination therapy with ezetimibe. Atherosclerosis 223:190–196PubMedCrossRef
Saeedi R, Johns K, Frohlich J, Bennett MT, Bondy G (2015) Lipid lowering efficacy and safety of ezetimibe combined with rosuvastatin compared with titrating rosuvastatin monotherapy in HIV-positive patients. Lipids Health Dis 14:57PubMedPubMedCentralCrossRef
Sager PT, Melani L, Lipka L, Strony J, Yang B, Suresh R, Veltri E (2003) Effect of coadministration of ezetimibe and simvastatin on high-sensitivity C-reactive protein. Am J Cardiol 92:1414–1418PubMedCrossRef
Sahebkar A, Watts GF (2013a) New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes. Clin Ther 35:1082–1098PubMedCrossRef
Sahebkar A, Watts GF (2013b) New therapies targeting apoB metabolism for high-risk patients with inherited dyslipidaemias: What can the clinician expect? Cardiovasc Drugs Ther 27:559–567PubMedCrossRef
Sahebkar A, Kotani K, Serban C, Ursoniu S, Mikhailidis DP, Jones SR, Ray KK, Blaha MJ, Rysz J, Toth PP, Muntner P, Lip GYH, Banach M (2015) Statin therapy reduces plasma endothelin-1 concentrations: a meta-analysis of 15 randomized controlled trials. Atherosclerosis 241:433–442PubMedCrossRef
Sahebkar A, Kiaie N, Gorabi AM, Mannarino MR, Bainaconi V, Jamialahmadi T, Pirro M and Banach M (2021) A comprehensive review on the lipid and pleiotropic effects of pitavastatin. Progress Lipid Res 84
Sakuma M, Toyoda S, Hashimoto R, Yazawa H, Masuyama T, Hirose S, Waku R, Hasumi H, Numao T, Abe S, Inoue T (2019) Add-on ezetimibe treatment to low-dose statins vs medium-intensity statin monotherapy in coronary artery disease patients with poorly controlled dyslipidemia. Hypertens Res 42:1923–1931PubMedCrossRef
Salazar J, Martínez MS, Chávez M, Toledo A, Añez R, Torres Y, Apruzzese V, Silva C, Rojas J, Bermúdez V (2014) C-reactive protein: clinical and epidemiological perspectives. Cardiol Res Pract 2014:605810PubMedPubMedCentralCrossRef
Sasaki J, Otonari T, Sawayama Y, Hata S, Oshima Y, Saikawa T, Biro S, Kono S (2012) Double-dose pravastatin versus add-on ezetimibe with low-dose pravastatin—effects on LDL cholesterol, cholesterol absorption, and cholesterol synthesis in Japanese patients with hypercholesterolemia (PEAS study). J Atheroscler Thromb 19:485–493PubMedCrossRef
Schandelmaier S, Briel M, Varadhan R, Schmid CH, Devasenapathy N, Hayward RA, Gagnier J, Borenstein M, van der Heijden G, Dahabreh IJ, Sun X, Sauerbrei W, Walsh M, Ioannidis JPA, Thabane L, Guyatt GH (2020) Development of the Instrument to assess the Credibility of Effect Modification Analyses (ICEMAN) in randomized controlled trials and meta-analyses. CMAJ 192:E901-e906PubMedPubMedCentralCrossRef
Shakour N, Ruscica M, Hadizadeh F, Cirtori C, Banach M, Jamialahmadi T, Sahebkar A (2020) Statins and C-reactive protein: in silico evidence on direct interaction. Arch Med Sci 16:1432–1439PubMedPubMedCentralCrossRef
Simons L, Tonkon M, Masana L, Maccubbin D, Shah A, Lee M, Gumbiner B (2004) Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome. Curr Med Res Opin 20:1437–1445PubMedCrossRef
Sohrevardi SM, Nasab FS, Mirjalili MR, Bagherniya M, Tafti AD, Jarrahzadeh MH, Azarpazhooh MR, Saeidmanesh M, Banach M, Jamialahmadi T, Sahebkar A (2021) Effect of atorvastatin on delirium status of patients in the intensive care unit: a randomized controlled trial. Arch Med Sci 17:1423PubMedCrossRef
Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM (2014) 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63:2889–2934PubMedCrossRef
Sudhop T, Reber M, Tribble D, Sapre A, Taggart W, Gibbons P, Musliner T, von Bergmann K, Lütjohann D (2009) Changes in cholesterol absorption and cholesterol synthesis caused by ezetimibe and/or simvastatin in men. J Lipid Res 50:2117–2123PubMedPubMedCentralCrossRef
Takemoto M, Liao JK (2001) Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 21:1712–1719PubMedCrossRef
Tan H, Liu L, Zheng Q, Zhang D, Liu Q, Cui D, Gao L, Wang Z, Wang WL, Liu J (2021) Effects of combined lipid-lowering therapy on low-density lipoprotein cholesterol variability and cardiovascular adverse events in patients with acute coronary syndrome. Adv Ther 38:3389–3398PubMedCrossRef
Toth PP, Catapano A, Tomassini JE, Tershakovec AMJCL (2010) Update on the efficacy and safety of combination ezetimibe plus statin therapy. Clin Lipidol 5:655–684CrossRef
Vahedian-Azimi A, Mohammadi SM, Beni FH, Banach M, Guest PC, Jamialahmadi T, Sahebkar A (2021) Improved COVID-19 ICU admission and mortality outcomes following treatment with statins: a systematic review and meta-analysis. Arch Med Sci 17:579–595PubMedPubMedCentralCrossRef
Vaverkova H, Farnier M, Averna M, Missault L, Viigimaa M, Dong Q, Shah A, Johnson-Levonas AO, Brudi P (2012) Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared to rosuvastatin 10 mg in high-risk patients with and without type 2 diabetes mellitus inadequately controlled despite prior statin monotherapy. Cardiovasc Ther 30:61–74PubMedCrossRef
Viigimaa M, Vaverkova H, Farnier M, Averna M, Missault L, Hanson ME, Dong Q, Shah A, Brudi P (2010) Ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk hypercholesterolemic patients stratified by prior statin treatment potency. Lipids Health Dis 9:127PubMedPubMedCentralCrossRef
Wang X, Zhao X, Li L, Yao H, Jiang Y, Zhang J (2016) Effects of combination of ezetimibe and rosuvastatin on coronary artery plaque in patients with coronary heart disease. Heart Lung Circ 25:459–465PubMedCrossRef
Wang J, Ai XB, Wang F, Zou YW, Li L, Yi XL (2017) Efficacy of ezetimibe combined with atorvastatin in the treatment of carotid artery plaque in patients with type 2 diabetes mellitus complicated with coronary heart disease. Int Angiol 36:467–473PubMedCrossRef
Whitehouse MW and Butters DE (2018) Lest we forget: the darker side of the hypocholesterolemic statin drugs. Pharmacogn Commun 8
Yamazaki D, Ishida M, Watanabe H, Nobori K, Oguma Y, Terata Y, Koyama T, Iino K, Kosaka T, Ito H (2013) Comparison of anti-inflammatory effects and high-density lipoprotein cholesterol levels between therapy with quadruple-dose rosuvastatin and rosuvastatin combined with ezetimibe. Lipids Health Dis 12:9PubMedPubMedCentralCrossRef
Yu D, Liao JK (2022) Emerging views of statin pleiotropy and cholesterol lowering. Cardiovasc Res 118:413–423PubMedCrossRef
Yuan F, Dong H, Gong J, Wang D, Hu M, Huang W, Fang K, Qin X, Qiu X, Yang X, Lu F (2019) A systematic review and meta-analysis of randomized controlled trials on the effects of turmeric and curcuminoids on blood lipids in adults with metabolic diseases. Adv Nutr 10:791–802PubMedPubMedCentralCrossRef
Yuan F, Wu W, Ma L, Wang D, Hu M, Gong J, Fang K, Xu L, Dong H, Lu F (2022) Turmeric and curcuminiods ameliorate disorders of glycometabolism among subjects with metabolic diseases: a systematic review and meta-analysis of randomized controlled trials. Pharmacol Res 177:106121PubMedCrossRef
Zhu Y, Hu H, Yang J, Yao Q, Xu H, Yu Y, Liu T, Lin S (2020) The efficacy and safety of statin in combination with ezetimibe compared with double-dose statin in patients with high cardiovascular risk: a meta-analysis. Bosn J Basic Med Sci 20:169PubMedPubMedCentral
Metadata
Title
The effect of statin therapy in combination with ezetimibe on circulating C-reactive protein levels: a systematic review and meta-analysis of randomized controlled trials
Authors
Seyyed Mostafa Arabi
Mahla Chambari
Mahsa Malek-Ahmadi
Leila Sadat Bahrami
Vahid Hadi
Manfredi Rizzo
Amirhossein Sahebkar
Publication date
21-08-2022
Publisher
Springer International Publishing
Published in
Inflammopharmacology / Issue 5/2022
Print ISSN: 0925-4692
Electronic ISSN: 1568-5608
DOI
https://doi.org/10.1007/s10787-022-01053-4

Other articles of this Issue 5/2022

Inflammopharmacology 5/2022 Go to the issue

Original Article

Metformin improves depressive-like behavior in experimental Parkinson’s disease by inducing autophagy in the substantia nigra and hippocampus

Review

Melatonin and multiple sclerosis: antioxidant, anti-inflammatory and immunomodulator mechanism of action

Original Article

Role of the NRG1/ErbB4 and PI3K/AKT/mTOR signaling pathways in the anti-psychotic effects of aripiprazole and sertindole in ketamine-induced schizophrenia-like behaviors in rats

Original Article

Diapocynin neuroprotective effects in 3-nitropropionic acid Huntington’s disease model in rats: emphasis on Sirt1/Nrf2 signaling pathway

Original Article

Therapeutic effect of the sulforaphane derivative JY4 on ulcerative colitis through the NF-κB-p65 pathway

Retraction Note

Retraction Note to: Phytofabricated silver nanoparticles of Phyllanthus emblica attenuated diethylnitrosamine‑induced hepatic cancer via knock‑down oxidative stress and inflammation